Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C

Journal of Hepatology

Volumn 28, Issue 3, 1998, Pages 375-381

  Leroy, Vincent ^a,b   Baud, Marilyne ^b   De Traversay, Caroline ^a   Maynard Muet, Marianne ^a   Lebon, Pierre ^c   Zarski, Jean Pierre ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b CNRS   (France)

^c HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Anti interferon antibodies; Breakthrough; Chronic hepatitis C; Recombinant alpha interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS REPLICATION;

EID: 0032030877     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80309-7     Document Type: Article

References (34)

1. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
3. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, et al. Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
4. Saracco G, Rosina F, Torrani-Cerenzia MR, Lattore V, Chiandussi L, Gallo V, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol. 11:1990;43-49. (Suppl. 1).
5. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long term follow-up of patients with chronic hepatitis C treated with alpha interferon. Hepatology. 15:1992;1013-1016.
6. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology. 24:1996;778-789.
7. Roffi L, Colleredo Mels G, Antonelli G, Bellati G, Panizzuti F, Piperno A, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and management. Hepatology. 21:1995;645-649.
8. Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal WS. The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome. Am J Gastroenterol. 90:1995;951-954.
9. Bellati G, Colloredo G, Roffi L, D'Acquino M, Bonino F, Ideo G. Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon. J Hepatol. 26:1997;449-450.
10. Hanley JP, Jarvis LM, Simmonds P, Ludlam CA. Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in hemophiliacs. Br J Haematol. 94:1996;551-556.
11. Pawlotsky JM, Bastie A, Roudot-Thoraval F, Darthuy E, Remiré J, Métreau JM, et al. Breakthrough during interferon therapy for chronic hepatitis C: evolution of HCV replication and evaluation of predictive factors [abstract]. Hepatology. 22:1995;114.
12. Lebon P, Daffos F, Checoury A, Forrestier F, Toublanc JE. Presence of an acid-labile alpha interferon in sera from fetuses and children with congenital rubella. J Clin Microbiol. 21:1985;775-778.
13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histoligical activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
14. Vallbracht A, Treuner J, Flehmig B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature. 289:1981;496-497.
15. Antonelli G, Currenti M, Turriziani O, Dianzan F. Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis. 163:1991;882-885.
16. Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (intron A). Am J Med. 80:1986;223-228.
17. Finter NB. Why are there so many subtypes of alpha-interferons? J Interferon Res. 1991;185-194. (Special Issue).
18. Carreno V, Wolfe L. Genotype dependant response to interferon alpha-2a in patients with chronic hepatitis C [abstract]. Hepatology. 22:1995;176.
19. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med. 318:1988;1409-1413.
20. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolome J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol. 8:1989;351-357.
21. Suk-Fong Lok A, Lai CL, Kit-Yee Leung E. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology. 12:1990;1266-1270.
22. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, et al. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver. 13:1993;146-150.
23. Bonetti P, Diodati G, Drago C, Casarin C, Scaccabarozzi S, Realdi G, et al. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a. J Hepatol. 20:1994;416-420.
24. Itri LM, Campion M, Dennin RA, Palleroni AV, Gutterman JU, Groopman JE, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant alfa-2a by intramuscular injection. Cancer. 59:1987;668-674.
25. Weck PK, Leventhal BG, Brand C, Finter NB. Detection and incidence of neutralizing antibodies to interferon alpha n1. J Interferon Res. 9:1989;37-43. (Suppl. 1).
26. Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, et al. A prospective randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology. 24:1996;1366-1370.
27. Billard C, Sigaux F, Castaigne S, Valensi F, Flandrin G, Degos L, et al. Treatment of hairy cell leukemia with recombinant alpha interferon: in vivo down-regulation of alpha interferon receptors on tumor cells. Blood. 67:1986;821-826.
28. Nakajima S, Kuroki T, Shiomi S, Seki S, Kobayashi K. Changes in interferon receptors on peripheral blood mononuclear cell from patients with chronic hepatitis B being treated with interferon. Hepatology. 12:1990;1261-1265.
29. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal of the E2/NS1 protien of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology. 16:1992;619-624.
30. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology. 22:1995;30-35.
31. Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, et al. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology. 108:1995;789-795.
32. Gonzalez-Peralta RP, Qian K, She JY, Davis GL, Ohno T, Mizokami M, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol. 49:1996;242-247.
33. Sakuma I, Enomoto N, Kurosaki M, Marumo F, Sato C. Seletion of hepatitis C virus quasispecies during interferon treatment. Arch Virol. 141:1996;1921-1932.
34. Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology. 24:1996;1018-1023.